Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 8/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 4/20 | 0.39 |
| ▸ | CSF1R | P07333 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21178987 | 0.79 | CYP1A2 (0.49) | CYP1A2CYP3A4ALDH1A1CYP2C19CLK4 | |
| SCHEMBL21179008 | 0.77 | CSF1R (0.41) | LRRK2HDAC8CSF1RNPC1RAB9A | |
| SCHEMBL21179116 | 0.76 | ALOX5 (0.38) | CYP1A2CYP3A4ALDH1A1CYP2C19CLK4 | |
| SCHEMBL21187309 | 0.76 | KIT (0.44) | ALDH1A1LRRK2HDAC8CSF1RHPGD | |
| SCHEMBL30823299 | 0.74 | PDE2A (0.43) | ALDH1A1LRRK2HDAC8CSF1RHPGD | |
| SCHEMBL21177909 | 0.74 | PDE2A (0.43) | ALDH1A1LRRK2HDAC8CSF1RHPGD | |
| SCHEMBL27201498 | 0.73 | NPC1 (0.47) | LRRK2HDAC8CSF1RNPC1RAB9A | |
| SCHEMBL21177865 | 0.72 | IP6K1 (0.44) | ALDH1A1LRRK2HDAC8CSF1RHPGD | |
| SCHEMBL21178784 | 0.71 | MAOB (0.45) | LRRK2HDAC8CSF1RNPC1RAB9A | |
| SCHEMBL21608846 | 0.70 | PIK3R1 (0.51) | CYP1A2CYP3A4ALDH1A1CYP2C19CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12269804-B2 | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-08 | — | — | US | disclosed |
| CN-111770921-B | Quinoxalinone compounds, compositions, methods and kits for improving genome editing efficiency | 沃泰克斯药物股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3740483-B1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMA (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3740483-B1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMA (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3740483-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | Vertex Pharmaceuticals Incorporated (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200361877-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-19 | — | — | US | disclosed |
| US-20200361877-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-19 | — | — | US | disclosed |
| CN-111770921-A | Quinoxalinone compounds, compositions, methods and kits for improving efficiency of genome editing | 沃泰克斯药物股份有限公司 | 2020-10-13 | — | — | CN | disclosed |
| WO-2019143677-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019143677-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361877-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | XRCC6, LIG1, DCK | CYP1A2 2175/4885CYP3A4 2257/4885ALDH1A1 2607/4885 |
| US-12269804-B2 | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency | XRCC6, LIG1, DCK | CYP1A2 2175/4885CYP3A4 2257/4885ALDH1A1 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.